Amphastar Pharmaceuticals (AMPH) Cash from Operations (2013 - 2026)

Amphastar Pharmaceuticals' Cash from Operations history runs 14 years deep, the most recent figure standing at 47840000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 36.39% year-over-year to 47840000.0 in Q1 2026; TTM through Mar 2026 was 168878000.0, a 12.58% decrease from a year earlier, with the FY2025 full-year figure at 156115000.0, down 26.84% from the prior year.
• Cash from Operations grew to 47840000.0 in Q1 2026 per AMPH's latest filing, from 32863000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 69109000.0 in Q2 2024 and bottomed at 2815000.0 in Q2 2022.
• The 5-year median for Cash from Operations is 40382000.0 (2023), against an average of 40589705.88.
• Across the five-year window, Cash from Operations tumbled 91.25% in 2022 and surged 1851.08% in 2023, its largest moves.
• Year by year, Cash from Operations stood at 15226000.0 in 2022, then jumped by 56.73% to 23864000.0 in 2023, then gained by 21.62% to 29024000.0 in 2024, then advanced by 13.23% to 32863000.0 in 2025, then soared by 45.57% to 47840000.0 in 2026.
• Per Business Quant, the three latest AMPH Cash from Operations figures stand at 47840000.0 (Q1 2026), 32863000.0 (Q4 2025), and 52583000.0 (Q3 2025).